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Abstract
Background: Buruli ulcer (BU) is a necrotizing bacterial infection of skin, subcutaneous tissue and bone caused by
Mycobacterium ulcerans. Although the functional impairment caused by BU results in severe suffering and in socio-
economic problems, the disease remains largely neglected in Africa. The province of Bas-Congo in Democratic Republic of
Congo contains one of the most important BU foci of the country, i.e. the Songololo Territory in the District of Cataractes.
This study aims to assess the impact of a BU control project launched in 2004 in the Songololo Territory.
Methods: We used a comparative non-randomized study design, comparing clinical profiles and outcomes of the group of
patients admitted at the General Reference Hospital (GRH) of the ‘‘Institut Me ´dical Evange ´lique’’ (IME) of Kimpese 3 years
before the start of the project (2002–2004) with those admitted during the 3 years after the start of the project (2005–2007).
Results: The BU control project was associated with a strong increase in the number of admitted BU cases at the GRH of
IME/Kimpese and a fundamental change in the profile of those patients; more female patients presented with BU, the
proportion of relapse cases amongst all admissions reduced, the proportion of early lesions and simple ulcerative forms
increased, more patients healed without complications and the case fatality rate decreased substantially. The median
duration since the onset of first symptoms however remained high, as well as the proportion of patients with osteomyelitis
or limitations of joint movement, suggesting that the diagnostic delay remains substantial.
Conclusion: Implementing a specialized program for BU may be effective in improving clinical profiles and outcomes in BU.
Despite these encouraging results, our study highlights the need of considering new strategies to better improve BU
control in a low resources setting.
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Introduction
Buruli ulcer (BU) is a necrotizing bacterial infection of skin,
subcutaneous tissue and bone, caused by an environmental
pathogen, Mycobacterium ulcerans [1]. Although the functional
impairment caused by BU results in severe suffering and in
socio-economic problems [2], the disease remains largely neglect-
ed by health authorities in Africa [3]. BU is considered as one of
the Neglected Tropical Diseases with a poorly known global
prevalence [4].
The province of Bas-Congo (Lower Congo) in the Democratic
Republic of Congo (DRC) contains one of the most important BU
foci of the country, i.e. the Songololo Territory in the District of
Cataractes [5–10]. Meyers et al. reported that BU existed in that
region before 1935 on the basis of interviews of former patients
[7]. The first BU case reports were published in the sixties [5–7]
followed by a long period without reported cases. Since 1999, the
general reference hospital (GRH) of the Institut Me ´dical
Evange ´lique (IME)/Kimpese, located in the Songololo Territory,
220 km southwest of Kinshasa, regularly admits BU cases.
www.plosntds.org 1 December 2011 | Volume 5 | Issue 12 | e1402Between 2002 and 2004 this hospital admitted 64 patients, 95% of
them in the ulcerative stage.
During this period, 48 patients out of 64 (75%) were referred by
government health centers or other health professionals, 9 (14.1%)
by family members, and 7 (10.9%) presented spontaneously.
Surgery was the main method of treatment applied amongst these
patients (93.7%). An abnormally high case fatality rate (18.7%)
was observed among these 64 patients, and whereas 36%
presented already a functional limitation at the time of diagnosis,
23% were discharged with permanent disability. The median
length of hospitalization was 89 days and, -noteworthy- 90% of the
patients were not able to pay their hospitalization costs.
To address these poor clinical outcomes, the American Leprosy
Mission and the IME hospital launched a BU control project in
Songololo Territory in 2004. The principal aims of this project
were (i) the improvement of the patient care of BU patients
admitted at the GRH IME/Kimpese and (ii) the promotion of
early community-based detection of suspected BU cases. The aim
of this study is to evaluate the impact of this specialized BU control
program on clinical profiles and outcomes.
Methods
Ethics Statement
Ethical clearance for this study was obtained from the
Institutional Review Board of IME. All patients, or their guardian
in the case of minors, provided informed consent for all diagnostic
and treatment procedures and publication of any or all images
derived from the management of the patient, including clinical
photographs that might reveal patient identity.
The BU control project started at the end of 2004 and introduced
free patient care for BU patients during their admission at GRH
IME/Kimpese, whereas this was hitherto to be paid on a fee-for-
service basis. Furthermore, the patients benefited from a free daily
nutritional supplement, and specific antibiotherapy was introduced
in accordance with WHO recommendations [11], as well as a
physiotherapy program for prevention of disabilities. Simultaneous-
lytheprojectorganizedawarenessraisingcampaignsintheendemic
communities, based on a mass-media approach targeting the
general public, followed by active case-finding and referral of
suspected cases to the specialized BU care centre. The project was
based on the following five components: Improving facilities’
management and treatment skills; Prevention of disabilities and
physical rehabilitation; Feeding patients and psychological and
social support for those affected; Stepping up Information,
Education and Communication for the general public and
community-based surveillance, and Training and research.
To evaluate the effect of this control project, we used a
comparative non-randomized study design, comparing patient
demographic profiles and clinical outcomes of the group of
patients admitted at the GRH IME/Kimpese in the 3 years before
the start of the project (2002–2004) with those admitted during the
3 years after the start of the project (2005–2007).
We have included all consecutive patients clinically diagnosed as
BU and admitted to the Surgical Department of GRH IME/
Author Summary
Buruli ulcer (BU), which is caused by Mycobacterium
ulcerans, is an important disabling skin disease. However,
BU has been neglected in many endemic African countries,
including in the Democratic Republic of Congo. The
province of Bas-Congo contains one of the most important
BU foci of the country, i.e. the Songololo Territory in the
District of Cataractes. In 2004 a specialized BU control
program was launched in that area. The present study
aims to evaluate the impact of the above-mentioned
program, by comparing clinical profiles and outcomes of
the group of patients admitted at the General Reference
Hospital (GRH) of the ‘‘Institut Me ´dical Evange ´lique’’ (IME)
of Kimpese 3 years before the start of the project (2002–
2004) with those admitted during the 3 years after the
start of the project (2005–2007). The project implementa-
tion was associated with a strong increase in the number
of admitted BU cases at the GRH and a fundamental
change in the profile of those BU patients. Despite these
encouraging results, our study provides some limitations
of such program, and highlights the need of considering
new strategies to better improve BU control in a low
resources setting.
Figure 1. Evolution of number of annual admissions of BU cases to the GRH IME/Kimpese from 2002 to 2007.
doi:10.1371/journal.pntd.0001402.g001
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definition elaborated by the World Health Organisation (WHO)
was used to diagnose BU [12]. Additionally for the second period,
as recommended by the WHO [11], we introduced patients’
categorization as follows: A single lesion ,5 cm (Category I); A
single lesion 5–15 cm (Category II); A single lesion .15 cm,
multiple lesions, lesions at critical sites (face, breast and genitalia)
or osteomyelitis (Category III). For all patients included in this
study, the diagnostic confirmation process consisted of swabs from
ulcerative lesions and biopsies for the laboratory confirmation
(bacteriology and/or histopathology) of suspected cases according
to WHO recommendations [12]. The initial direct smear
examinations for acid-fast bacilli and histopathologic analyses
were made at the IME/Kimpese laboratory. Other specimens
from the same patient were sent in a transport medium to the
Mycobacteriology Unit of the Institute of Tropical Medicine
(ITM) in Antwerp, Belgium [13], where Ziehl-Neelsen (ZN)
staining, in vitro culture on Lo ¨wenstein-Jensen medium, and PCR
for the detection of M. ulcerans DNA were performed according to
WHO recommendations [12]. Formalin-fixed tissues were sent to
the Department of Infectious and Parasitic Diseases Pathology of
the Armed Forces Institute of Pathology in Washington DC, for
the histopathological confirmation of diagnosis [10].
Throughout the whole study period, clinical data of BU patients
were recorded on standardized Case Report Forms elaborated by
WHO (known as form BU01) and the data were entered in a
standardized case registry form (BU02) [14]. Next, these data were
entered into an Excel database (Microsoft Corporation, Redmond,
WA) and analyzed with Epi-Info version 3.3.2 (Centers for
Diseases Control and Prevention, Atlanta, GA). The Pearson chi-
Table 1. The clinico-epidemiological features of BU patients at admission in IME/Kimpese Hospital.
2002–2004 2005–2007 p
Number of suspected BU cases 64 190
Average number of annual admissions 21 63
Classification of cases (%)
New case 67.2 (43/64) 88.4 (168/190) ,0.001
Relapse 32.8 (21/64) 11.6 (22/190) ,0.001
Ulcerative forms at detection (%) 95.3 (61/64) 85.8 (163/190) 0.041
Clinical Forms (%)
Mixed ulcerated forms 64 (41/64) 33.7 (64/190) ,0.001
Simple ulcerated forms 31.3 (20/64) 52.1 (99/190) 0.003
Simple ulcerated forms amongst the ulcers 32.8 (20/61) 60.7 (99/163) ,0.001
Edema 1.5 (1/64) 3.7 (7/190) 0.358*
Nodule 0 2.6 (5/190) 0.231*
Papule 0 0
Plaque 1.5 (1/64) 2.1 (4/190) 0.628*
Non ulcerative mixed forms 1.5 (1/64) 2.1 (4/190) 0.628*
Suspected osteomyelitis 29.7 (19/64) 14.7 (28/190) 0.007
Confirmed osteomyelitis 14 (9/64) 9.5 (18/190) 0.302
Sites of lesions (%)
Lower limb 65.6 (42/64) 68.4 (130/190) 0.679
Upper limb 35.9 (23/64) 25.8 (49/190) 0.119
Thorax 3.1 (2/64) 2.1 (4/190) 0.471*
Back 4.7 (3/64) 1.6 (3/190) 0.170*
Head and neck 6.3 (4/64) 8.9 (17/190) 0.497
Abdomen 0 1.1 (2/190) 0.558*
Buttock and perineum 0 0.5 (1/190) 0.748*
Disability at admission (%) 36 (23/64) 25.8 (49/190) 0.119
Distribution by age in years (%)
#15 35.9 (23/64) 40 (76/190) 0.564
16–45 37.5 (24/64) 42.1 (80/190) 0.516
.45 26.6 (17/64) 17.9 (34/190) 0.134
Median age (years) 19.5 21
Sex ratio (M/F) 2.4/1 (45/19) 1.02/1 (96/94)
Proportion of female patients (%) 30 (19/64) 49 (94/190) 0.005
Median delay of disease before detection
(weeks)
68
*Fisher exact test (An expected cell value is less than 5).
doi:10.1371/journal.pntd.0001402.t001
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level set at 5%, as well the Fisher’s exact test when an expected cell
value was less than 5.
To evaluate the relevance and the effect of the BU control
project, we used the conceptual framework to evaluate public
health programs proposed by Habicht et al. [15]. The principal
indicators considered for the data analysis are the number of
recorded cases for each period, the number of new cases and
relapses, the proportion of cases with functional limitation of joints
at diagnosis, the proportion of cases confirmed by at least one
laboratory test, the proportion of ulcerative forms at diagnosis, the
type of treatment applied, the proportion of discharged cases with
functional limitation of joints, the median duration of hospitaliza-
tion, and the case-fatality rate. Relapse was defined in both study
periods as a new confirmed diagnosis of BU less than one year
after being declared cured from BU after treatment (surgical only
in the first period, antibiotic and/or surgical in the second period).
Functional limitation was defined as any reduction in the range of
motion of one or more joints, and was assessed based on clinical
observation.
Lesions were considered as mixed forms when simultaneous
presence of different forms of disease including bone and joint
involvement in the same patient was noticed. Besides, we defined
as simple ulcerative forms (SUF) the ulcerative lesions not
associated with other clinical lesions such as papule, nodule,
plaque, edema or osteomyelitis at the same site.
Results
The number of suspected BU cases admitted at GRH IME/
Kimpese strongly increased after the start of the BU control
project. The average number of annual admissions for BU tripled,
from 21 cases per year for the period 2002–2004, to 63 cases per
year for 2005–2007 (Figure 1). The clinico-epidemiological
features and the results of patient management are shown in
Tables 1 and 2. The origin of patients remains mainly the
Songololo Territory, Cataractes District, where the GRH IME/
Kimpese is located (Figure 2). The median age of patients (20
years) was similar for both periods. The proportion of female
patients increased significantly from 30% before to 49% after the
project was initiated (p=0.005).
In both periods, the majority of BU patients were new cases, yet
the proportion of relapse cases amongst all admissions reduced
from 32.8% to 11.6% (p,0.001) after 2004.
The proportion of ulcerative forms at admission decreased from
95.3% to 85.8% after 2004 (p=0.041), and the proportion of SUF
increased from 32.8% to 60.7% amongst the ulcers (p,0.001)
(Figure 3). There was no change in the proportion of confirmed
osteomyelitis nor in the proportion of patients presenting with joint
movement limitations. The reported median duration of the
disease since the appearance of first symptoms increased from 6 to
8 weeks. Globally, the proportion of patients who healed with
complications did not change significantly from 23.4% to 19.5%
(p=0.496), even amongst patients declared cured only, from
31.3% to 21.0% (p=0.136).
However, the number of cases that healed without complica-
tions increased significantly from 51.6 to 73.2% (Figure 4)
(p=0.001). The proportion of cases confirmed by at least one
laboratory test positive for M.ulcerans remained the same (70% in
2002–2004 versus 61% in 2005–2007, p=0.183).
Antibiotic therapy was introduced as part of the control project,
and was prescribed to 56.3% of patients, although most patients
Table 2. Results of the management of BU patients in IME/Kimpese Hospital.
2002–2004 2005–2007 p
Healed with disability (%)
Amongst all admitted patients 23.4 (15/64) 19.5 (37/190) 0.496
Amongst patients declared cured 31.3 (15/48) 21.0 (37/176) 0.136
Mode of/State at discharge (%)
Death due to BU 18.7 (12/64) 3.2 (6/190) ,0.001*
Healed with complications 23.4 (15/64) 19.5 (37/190) 0.496
Healed without complications 51.6 (33/64) 73.2 (139/190) 0.001
Patients self-discharged 4.7 (3/64) 2.6 (5/190) 0.325*
Transferred 1.6 (1/64) 1.1 (2/190) 0.583*
Patient still under treatment 0.5 (1/190)
Laboratory confirmed patients (%)
2002 88 (14/16) 2005 61 (25/41) 0.052
2003 55 (12/22) 2006 62 (46/74) 0.521
2004 73 (19/26) 2007 60 (45/75) 0.233
Total 70 (45/64) Total 61 (116/190) 0.183
Treatment applied (%)
Rifampin & streptomycin 0 (0/64) 56.3 (107/190) 0
Surgery 93.7 (60/64) 84.2 (160/190) 0.052
Prevention of disability _ 6
Median duration of hospitalization (days) 89 85
Case Fatality rate 18.7 (12/64) 3.2 (6/190) ,0.001*
*Fisher exact test (An expected cell value is less than 5).
doi:10.1371/journal.pntd.0001402.t002
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84.2% after 2004, p=0.052). Ninety patients (47.4%) were treated
by a combination of antibiotics (rifampicin and streptomycin) and
surgery. Seventy patients (36.8%) were treated with surgery alone,
seventeen patients (8.9%) only with antibiotics, and thirteen (6.8%)
were treated with daily wound dressing.
The median duration of hospitalization, around 90 days, was
approximately similar during both periods (Table 2) and varied by
disease category during the second period, respectively 60 days for
category I (Figure 5 and 6), 81 days for category II, and 118 days
for category III.
The case fatality rate was significantly decreased from 18.7%
during the previous period (12 out of 64 patients) to 3.2% (6 out of
190 patients) during the second period (p,0.001). Conditions
associated with mortality among BU patients in the previous
period were as follows: sepsis in four patients out of twelve (33%),
malnutrition and anaemia in nine patients (75%), edematous
disseminated disease in two patients (16.6%), postsurgical shock in
one patient (8%), and cancerization in two patients (16.6%).
Discussion
The BU control project was associated with a strong increase in
the number of admitted BU cases at GRH IME/Kimpese and a
fundamental change in the profile of those BU patients. Since the
implementation of the control project we observed equal numbers
of men and women presenting with BU, significant decrease in the
proportion of relapse cases and significant increases in the
proportion of early lesions and simple ulcerative forms, and in
the proportion of patients healed without complications. Impor-
tantly, the case fatality rate decreased significantly from 18.7% to
3.2%.
While those parameters indicate a positive impact of the project,
we are aware of the limitations of our study. For our evaluation,
we used a historical control group: BU patients admitted at the
hospital before the project (2002–2004) were compared to those
who benefited from the implementation of the control project
(2005–2007). Although such before/after evaluation design does
not provide conclusive evidence that the observed changes are
Figure 2. Origin of BU patients admitted in IME/Kimpese Hospital, 2002–2007.
doi:10.1371/journal.pntd.0001402.g002
Figure 3. A simple ulcerated form of disease on the right arm.
doi:10.1371/journal.pntd.0001402.g003
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sufficient by policy makers to conclude to a beneficial effect [15].
The threefold increase in the number of BU cases admitted
annually can to a large extent be explained by the active case-
finding and the reduction of the financial barrier, as patient care
was free after 2004, but is probably also due to the improvement of
patient management and the quality of clinical results. While both
aspects are likely partially involved in the observed results, the
observational study design will not allow us to distinguish between
the two.
The capacity strengthening of medical staff on the surgical
management of BU patients through local and international
training, the introduction of specific antibiotherapy (rifampicin
and streptomycin), and implementation of a program for the
prevention of disabilities have contributed to improvement of
clinical outcomes (the increased proportion of patients healed
without complications, the reduction of the proportion of relapses,
and the reduction of the case fatality rate). Furthermore, we
assume that the improved access to adequate and prompt BU
treatment in the second period through the free patient care, and
the free daily nutritional supplement offered played a major role in
the improvement of clinical outcomes during the second period.
Indeed, in Africa, the challenge for health care professionals
working with BU patients is to break up the cycle of poor clinical
outcomes leading to loss of confidence of the affected communities
in the hospital [16]. Debacker et al. reported that in the Centre
Sanitaire et Nutritionnel Gbemoten (CSNG), Zagnanado, Benin,
68.3% of patients were referred to the hospital by a former BU
patient. The improved quality of care at CSNG resulted in a
reduction of the median duration of hospitalization from 9 months
in 1989 to 1 month in 2001, and the median delay in seeking
medical care dropped from 4 months in 1989 to 1 in 2001 [17].
The introduction of a BU program was an important factor in the
marked reduction in patient delay. Furthermore, after promotion-
al sessions on BU organized in 2000 by the National BU program
in the Zou, Oueme, and Atlantique Departments, patients
reported earlier than in 1999 [17]. We are hopeful that similar
results will develop at the Territory of Songololo in Bas-Congo.
Awareness raising campaigns followed by active case-finding
have contributed to the dissemination of information on BU
among the communities in Songololo during the intervention
period. We assume that the active case-finding activities have
contributed to the change of the Male/Female ratio from 2.4/1
before the project to 1.02/1 during the project period, and thus,
the project seems to have contributed to equilibrate the gender
balance. During the first period, male BU patients were more
frequent probably due to sociocultural barriers for women to seek
Figure 4. Healing without complications after antibiotherapy combined with surgery.
doi:10.1371/journal.pntd.0001402.g004
Figure 5. Single ulcerative lesion ,5 cm diameter (confirmed
by IS2404-PCR).
doi:10.1371/journal.pntd.0001402.g005
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activities helped the female patients to overcome these barriers.
Progressively, more early lesions and more SUF were diagnosed
at the hospital. However, rather surprisingly, the median duration
since the onset of first symptoms remained high after the project
was launched. Reasons why the median delay in seeking medical
attention was higher during the second period compared to the
first one remain unclear, and need to be assessed. This may
explain the fact that the number of confirmed osteomyelitis cases,
limitations of joint movement, both at diagnosis as well as at
healing, and patients needing surgery, remained similar. This is
problematic, as the huge clinical impact of BU is mainly due to the
late detection of cases [18]. Indeed, an extended delay before
presentation to the hospital has been identified as one of the most
important risk factors for bone involvement. Between 1996 and
2007, out of 930 confirmed and treated BU patients at
Zagnanado, Benin, 106 (11.4%) presented an osteomyelitis caused
by M. ulcerans. The median delay between onset of symptoms and
consultation was 167 days for patients with bone involvement and
61 days for those with cutaneous lesions (p,0.001) [19]. In most
endemic regions, consulting the hospital seems to be the last resort
when other attempts were unsuccessful and when the disease has
reached an advanced stage with large cutaneous ulcerations or
other complications, such as joint contractures or osteomyelitis
[19]. Stienstra et al. reported in their study on the beliefs and
attitudes towards BU in Ghana that in 59% of cases, witchcraft
was mentioned as cause of the disease. Among the interviewed
patients, 52% applied herbs on their lesions and consulted a
hospital as last resort. The reasons evoked were (i) financial
difficulties [30]% of patients), (ii) the fear of treatment at the
hospital and in particular amputation, and (iii) expectations of a
spontaneous healing [20]. Recently, a study conducted by
Renzaho et al. in Ga West district in Ghana demonstrated that
71.8% of BU patients consulted a traditional practitioner first and
that the hospital was consulted as last resort [16]. Meyers and
others noted that in the Songololo Territory, DRC, the reasons for
which many BU patients delayed seeking medical assistance were
obviously complex, but cultural, economic, and transportation
factors were especially important [7]. Recently, a study conducted
in the same area showed that all interviewed patients first adopted
a ‘‘wait and see’’ attitude which lasted on average 2 months [21].
Similar observations were reported in other African countries as
Cameroun [22], and Benin [23–25]. Those studies were realized
when surgery was still the treatment of choice; the recent
introduction of specific antibiotherapy as first line treatment may
alter this behavior [26–28].
These social, economical, geographical and cultural reasons,
that limit the access to health care in endemic regions, suggest that
the number of admitted patients at GRH IME/Kimpese may
represent only the emerged part of the iceberg. The free of charge
policy offered to patients does not resolve completely the problem
of financial barriers related to the patient management of BU. The
study conducted by Grietens et al. in two hospitals with a
specialized program for BU in Cameroun, similar to ours, has
shown that in spite of the reduction of the treatment costs, the
hospitalization for BU remains financially and socially untenable
for patients and their households, leading to the abandonment of
biomedical treatment or a complete refusal [29]. Therefore, there
is a need to consider new control strategies which are both socially
and financially acceptable and appropriate for the concerned
communities.
Conclusion
Overall, the results after 3 years of implementation of BU
control activities in Songololo Territory are encouraging. Howev-
er, the morbidity and disabilities due to BU remain high among
our patients. The burden of BU in terms of human suffering, long
duration of hospitalization, the development of disabling sequelae,
and socio-economic repercussions, is mainly attributable to the
late detection of cases. For this reason, secondary prevention
Figure 6. Healed lesion without complication after antibiotherapy alone without surgery.
doi:10.1371/journal.pntd.0001402.g006
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key measures in the control of BU [30].
To reduce the burden and to increase the coverage of the
population at risk, we consider that a dedicated BU control
program at central and provincial level, that operates in close
collaboration with the existing polyvalent health services, would be
the most efficient way to organize the control of BU in Songololo
Territory. The aforesaid program should involve education of the
population in the endemic areas, training of healthcare workers,
early detection by active case-finding and adequate case
management provided free of charge. Further decentralization
and integration of BU control activities may improve access to
diagnosis and care at the most peripheral level of the health
system. A close collaboration between the BU control project and
the health zones is essential for the implementation of a simple,
functional, and efficient active surveillance system in a resource-
limited context.
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